Looking to offset a patent cliff that could cut sales by up to $2.75B this year, Pfizer (PFE) is...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Looking to offset a patent cliff that could cut sales by up to $2.75B this year, Pfizer (PFE) is among the companies reportedly interested in acquiring Agila Specialties, the injectable-medicines unit of India's Strides Arcolab. Novartis (NVS), Mylan (MYL) and Fresenius (APCVZ) have also been eyeing Agila, which produces cancer treatments and antibiotics, and could be valued at $2B.